Japan's Ministry Continues Safety Measures On AstraZeneca's Iressa
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare's Pharmaceutical Safety Committee decided August 1 to continue current safety measures and side effects monitoring regarding AstraZeneca's lung cancer drug Iressa (gefitinib). The committee also summarized and confirmed the drug's clinical benefits. Since last February, the committee has conducted trials comparing gefitinib with other AstraZeneca cancer drugs, and the committee concluded that the results need further analyzing. Iressa has been the center of attention since serious side effects were reported in Japan. (Click here for more - Japanese language